DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 39.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,939,537 shares of the medical device company's stock after selling 1,275,532 shares during the period. Price T Rowe Associates Inc. MD owned 0.50% of DexCom worth $150,839,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Watts Gwilliam & Co. LLC purchased a new stake in DexCom during the 4th quarter worth approximately $3,334,000. Congress Asset Management Co. increased its stake in DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after buying an additional 1,332,522 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in DexCom by 2,226.6% during the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock worth $18,085,000 after buying an additional 222,548 shares in the last quarter. First Hawaiian Bank grew its position in shares of DexCom by 556.1% in the fourth quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company's stock valued at $1,801,000 after purchasing an additional 19,629 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $5,812,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Down 1.7 %

NASDAQ DXCM traded down $1.19 during trading on Thursday, reaching $70.19. 4,443,245 shares of the company's stock were exchanged, compared to its average volume of 4,213,778. The stock has a market cap of $27.52 billion, a P/E ratio of 49.09, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a 50 day moving average price of $72.01 and a two-hundred day moving average price of $76.67. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Mizuho assumed coverage on DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price for the company. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and raised their target price for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Citigroup raised their price target on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Finally, Morgan Stanley raised their price target on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $99.00.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the sale, the executive vice president now directly owns 135,482 shares in the company, valued at $10,002,636.06. This trade represents a 4.91 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 66,926 shares of company stock worth $4,734,384. 0.32% of the stock is owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.